The Real Problem With Modern Healthcare

“You don’t need to leave the U.S. to get real stem cell therapy.” – Seth BergeIn this episode of Compound Wisdom, Steve Sood sits down with Seth Berge, founder of Regenerative Revival, to unpack what’s really holding back regenerative medicine—and why the problem isn’t the science, but the system delivering it.Seth shares his unconventional path from high-ticket direct-to-consumer sales into the stem cell space, revealing how real demand and promising outcomes were being undermined by friction, poor communication, and broken follow-up models. Together, they explore how education-first selling, concierge care, and compliant systems can dramatically improve patient outcomes while still allowing the business to scale.The conversation dives deep into stem cell myths, why leaving the U.S. for treatment is often unnecessary, and how regulation—when done right—can actually become a competitive advantage. Seth also explains the growing role of IV stem cells and exosomes in wellness, longevity, and inflammation support, along with where the regenerative health industry is heading next.TakeawaysFriction in healthcare kills trust, outcomes, and conversionGreat medicine often fails because of broken delivery systemsEducation-first models outperform traditional clinic sellingStem cells can be explained without medical jargonYou don’t need to leave the U.S. for legitimate stem cell accessFDA “non-approval” does not mean illegal or ineffectiveCultured and expanded cells overseas carry unknown risksIV stem cells and exosomes are emerging wellness toolsConcierge, mobile care improves patient experience and scaleRegulation can eliminate bad actors and reward compliant operatorsChapters00:01 Friction Kills Conversion02:07 Seth’s Entry Into Stem Cells Through Sales04:13 Full Rooms, Zero Conversions05:42 Removing Friction From the Model06:22 Why Dinner Seminars Still Work09:12 Stem Cells Explained Simply11:14 The Overseas Stem Cell Myth13:47 Cultured Cells vs Non-Manipulated Tissue15:42 Marketing Limits in the U.S.17:01 IV Stem Cells and Exosomes19:31 How Often to Use Stem Cells for Optimization20:24 Pricing, Access, and Market Maturity22:30 Helping Med Spas Enter the Space25:16 Addressing Skepticism and Credibility28:07 Concierge, At-Home Treatment30:10 Regulation and the Future of Regenerative Medicine34:19 Biggest Risks in Telehealth35:59 Learning From Competitors